BeiGene Announces Global Strategic Oncology Collaboration with Amgen
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
? Companies to Collaborate on the Commercialization of XGEVA??(denosumab), KYPROLIS?(carfilzomib), and BLINCYTO??(blinatumomab) in?China
??Companies to Jointly Develop 20 Amgen Oncology Pipeline Assets, with BeiGene Responsible for Development and Commercialization in?China?as Part of the Global Development Plan
??Amgen to Purchase Approximately?$2.7 Billion?of BeiGene Shares
??BeiGene to Hold Analyst and Investor Call on Thursday, October 31?at?8:00 p.m. ET
CAMBRIDGE, Mass.?and?BEIJING, China,?Oct. 31, 2019?(GLOBE NEWSWIRE) --?BeiGene, Ltd.(NASDAQ: BGNE; HKEX: 06160) and?Amgen?(NASDAQ: AMGN) today announced a global strategic oncology collaboration for the commercialization and development in?China?of Amgen?s XGEVA??(denosumab), KYPROLIS??(carfilzomib), and BLINCYTO??(blinatumomab), and the joint global development of 20 oncology assets in Amgen?s pipeline, with?BeiGeneresponsible for development and commercialization in?China. In connection with the collaboration,?Amgen?will purchase a 20.5% stake in?BeiGene?for approximately?$2.7 billion?in cash at?$174.85?per American Depositary Share (ADS). ?Through this collaboration,?Amgen, a true biotech pioneer and leader in our industry, has recognized the transformative potential of BeiGene?s unique clinical development capabilities to accelerate global drug development. We are thrilled to join forces with?Amgen?to realize the development and commercialization of this broad oncology pipeline with the aim of benefitting patients around the world,? said?John V. Oyler, Co-Founder, CEO, and Chairman of?BeiGene. ?In addition, this alliance expands the portfolio available to our market-leading?China?commercial team, led by Dr.?Xiaobin Wu, with the potential to bring as many as eight internally discovered and in-licensed innovative treatments to cancer patients by the end of 2020.? ?This strategic collaboration with?BeiGene?will enable?Amgen?to serve significantly more patients by expanding our reach in the world?s most populous country. We?ve chosen an innovative strategic collaborator that can offer commercial and clinical reach with global quality standards,? said?Robert A. Bradway, Amgen?s chairman and chief executive officer. ?Cancer is a leading cause of death in?China?and will only become a more pressing public health issue as the Chinese population ages. We look forward to working with?BeiGene?to make a meaningful difference in the lives of millions of cancer patients in?China?and around the world.? Key elements of the collaboration include: Commercialization of Approved Products in?China:- Under the agreement,?BeiGene?will commercialize XGEVA, KYPROLIS and BLINCYTO in?China?for five or seven years, during which time the parties will equally share profits and losses. Following the commercialization period,?BeiGene?will have the right to retain one product and will be entitled to receive royalties on sales in?China?for an additional five years on the products not retained; and
- XGEVA (denosumab) was approved in?China?in 2019 for patients with giant cell tumor of the bone and is in development for prevention of skeletal-related events in cancer patients with bone metastases. KYPROLIS (carfilzomib) is in late-stage development in?China?for patients with multiple myeloma, and BLINCYTO (blinatumomab) is in late-stage development in?China?as a treatment for adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
- BeiGene?has agreed to jointly develop 20?Amgen?oncology pipeline assets globally, which include targeted small-molecule agents such as AMG 510, a first-in-class investigational KRAS G12C inhibitor, as well as BiTE??(Bispecific T cell Engager) antibodies, for solid and hematologic malignancies;
- Amgen?and?BeiGene?will co-fund global development costs, with?BeiGene?contributing up to?$1.25 billion?worth of development services and cash over the term of the collaboration.?BeiGene?is entitled to receive royalties from global sales of each product outside of?China, with the exception of AMG 510;
- For each pipeline asset that is approved in?China,?BeiGene?will receive commercial rights for seven years from approval, during which time the parties will share equally in profits and losses.?BeiGene?is also entitled to receive royalties from sales in?China?for five years after the seven-year commercial term; and
- BeiGene?will also have the right to retain approximately one of every three approved pipeline assets, up to a total of six, other than AMG 510, for commercialization in?China, during which time the parties will share in profits and losses.
BeiGene Investor Contact | BeiGene Media Contact |
Craig West | Liza Heapes or Vivian Ni |
+1 857-302-5189 | +1 857-302-5663 or +1 857-302-7596 |
ir@beigene.com | media@beigene.com |